PMID- 25433918
OWN - NLM
STAT- MEDLINE
DCOM- 20150924
LR  - 20181113
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 34
IP  - 2
DP  - 2015 Feb
TI  - Methotrexate revisited: considerations for subcutaneous administration in RA.
PG  - 201-5
LID - 10.1007/s10067-014-2830-9 [doi]
AB  - Rheumatoid arthritis (RA) is associated with significant disability, morbidity, 
      early mortality, and substantial financial burden. Despite newer antirheumatics, 
      methotrexate (MTX) remains the most widely used disease-modifying antirheumatic 
      drug. Subcutaneous (SC) MTX provides consistent, reliable delivery, with improved 
      absorption and enhanced polyglutamization leading to increased response rates and 
      fewer gastrointestinal side effects than oral MTX. Optimizing MTX with use of the 
      SC formulation can improve outcomes and may delay or negate the need for costly 
      biologics.
FAU - Jay, Randy
AU  - Jay R
AD  - Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, USA, 
      usjays@cox.net.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141130
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antirheumatic Agents/*administration & dosage/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Methotrexate/*administration & dosage/therapeutic use
EDAT- 2014/12/01 06:00
MHDA- 2015/09/25 06:00
CRDT- 2014/12/01 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2014/11/09 00:00 [accepted]
PHST- 2014/12/01 06:00 [entrez]
PHST- 2014/12/01 06:00 [pubmed]
PHST- 2015/09/25 06:00 [medline]
AID - 10.1007/s10067-014-2830-9 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2015 Feb;34(2):201-5. doi: 10.1007/s10067-014-2830-9. Epub 2014 
      Nov 30.